Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-0610 plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor–naive myelofibrosis
2020-001989-10Phase 3Active
- Sponsor
- Constellation Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing CPI-0610 + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Splenic response at Week 24. Started Oct 2020; status: active.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-001989-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001989-10.